共 50 条
- [31] Sequencing bispecific antibodies and CAR T cell therapy in multiple myeloma with prior exposure to BCMA-targeted therapies.JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Patel, UrviOluwole, Olalekan O.Kassim, AdetolaJayani, ReenaBelliveau, PaulSavani, BipinDholaria, Bhagirathbhai R.
- [32] RG6234, a GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Intravenous (IV) and First Subcutaneous (SC) Results from a Phase I Dose-Escalation StudyBLOOD, 2022, 140Carlo-Stella, CarmeloMazza, RitaManier, SalomonFacon, ThierryYoon, Sung-SooKoh, YoungilHarrison, Simon J.Er, JeremyPinto, AntonioVolzone, FrancescoPerrone, GiuliaCorradini, PaoloCazaubiel, TitouanHulin, CyrilleTouzeau, CyrilleMoreau, PhilippeOcio, Enrique M.Gaisan, Carmen Maria MontesPopat, RakeshLeong, SarahOffner, FritzOtero, Paula RodriguezAlfonso-Pierola, AnaBroeske, Ann-Marie E.Dekhtiarenko, IrynaHelms, Hans-JoachimBelli, SaraRossmann, EvaFauti, TanjaEckmann, JanMoore, TomSchneider, MeikeJacob, WolfgangWeisser, MartinHutchings, MartinRiley, Caroline Hasselbalch
- [33] Real-World Safety and Efficacy of Talquetamab for Patients with Heavily Pretreated Relapsed-Refractory Multiple MyelomaCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S87 - S88Shaikh, HiraLochner, JonathanFriend, ReedSnyder, JordanDavis, JamesPatrus, GinaDileo, RachelAhmed, NausheenMewawalla, PrernaPoonsombudlert, KittikaStruble, EmilyWolcott, AllysonGreen, KimberlySparrow, SamanthaMushtaq, Muhammad UmairPaul, BarryAbdallah, Al-OlaStrouse, ChristopherHashmi, HamzaAtrash, Shebli
- [34] Elranatamab, a BCMA Targeted T-Cell Engaging Bispecific Antibody, Induces Durable Clinical and Molecular Responses for Patients with Relapsed or Refractory Multiple MyelomaBLOOD, 2022, 140Raje, NoopurBahlis, Nizar JacquesCostello, CaitlinDholaria, BhagirathbhaiSolh, MelhemLevy, Moshe YairTomasson, Michael H.Damore, Michael A.Jiang, SiboBasu, CynthiaSkoura, AthanasiaChan, Edward M.Trudel, SuzanneJakubowiak, AndrzejChu, Michael P.Gasparetto, Cristina J.Dalovisio, Andrew P.Sebag, MichaelLesokhin, Alexander M.
- [35] Daratumumab triplet therapies in patients with relapsed or refractory multiple myeloma: A "real world" experienceLEUKEMIA RESEARCH REPORTS, 2022, 17Fucci, LudovicaGensini, LorenzoCoppetelli, UgoLa Barbera, Elettra OrtuGentile, MartinaFiori, LucianoPerrone, SalvatoreCimino, Giuseppe
- [36] Real-World Safety and Early Efficacy of Talquetamab in Patients with Heavily-Pretreated Relapsed/Refractory Multiple MyelomaCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S46 - S47Costa, BrunoTan, CarlynShekarkhand, TalaFirestone, RossJurgens, EricMiller, KevinLesokhin, AlexanderShah, GunjanKorde, NehaRajeeve, SrideviChung, DavidLandau, HeatherScordo, MichaelHassoun, HaniMaclachlan, KyleeShah, UrviHultcrantz, MalinHamadeh, IssamGiralt, SergioMailankody, ShamUsmani, SaadHashmi, Hamza
- [37] Characterization of dysgeusia and xerostomia in patients with multiple myeloma treated with the T-cell redirecting GPRC5D bispecific antibody talquetamabSupportive Care in Cancer, 2024, 32A. M. G. A. LaheijN. W. C. J. van de Donk
- [38] Cumulative Incidence and Characteristics of Infections Requiring Treatment, Delay in Treatment Administration or Hospitalisation in Patients with Relapsed or Refractory Multiple Myeloma Treated with Anti BCMA or Anti GPRC5D Bispecific AntibodiesBLOOD, 2023, 142Cellerin, EliseJourdes, AurelieBrousse, XavierVallet, NicolasCartau, TomDenis, BlandineHarel, StephanieJamard, SimonRedor, AlexisCazaubiel, TitouanRoland, VirginieCaleteix, CarineCharles, MorganeBerger, PierreEscure, GuillaumeCollignon, AudeFaure, EmmanuelCazelles, ClarisseLanternier, FannyVaux, Clementine De La Porte DesFrenzel, LaurentBlot, MathieuDanion, FrancoisSonntag, CecileTouzeau, CyrillePieragostini, AndreaAder, FlorenceKarlin, LionelMacro, MargaretMartin-Blondel, GuillaumeChalopin, ThomasPerrot, Aurore
- [39] Characterization of dysgeusia and xerostomia in patients with multiple myeloma treated with the T-cell redirecting GPRC5D bispecific antibody talquetamabSUPPORTIVE CARE IN CANCER, 2024, 32 (01)Laheij, A. M. G. A.van de Donk, N. W. C. J.
- [40] Real-World Outcomes of Patients with Relapsed/Refractory Multiple Myeloma Treated with Teclistamab and Talquetamab; A Multicenter Analysis from the Greek Myeloma Study GroupBLOOD, 2024, 144 : 6988 - 6990Ntanasis-Stathopoulos, IoannisKatodrytou, EiriniHatjiharissi, EvdoxiaSpanoudakis, EmmanouilDouka, VasilikiFotiou, DespinaLabropoulou, VasilikiDalampira, DimitraSpiliopoulou, VasilikiPapadopoulou, TheodosiaChristoulas, DimitriosMalandrakis, PanagiotisBouchla, AnthiPappa, VasilikiKastritis, EfstathiosTerpos, EvangelosDimopoulos, MeletiosGavriatopoulou, Maria